Trial Search Results

Prospective Observational Epidemiologic Study of Maraviroc's Safety

The study will assess if use of maraviroc along with an optimized background regimen of antiretroviral drugs in usual clinical practice is as safe as using only an optimized regimen of antiretroviral drugs.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

ViiV Healthcare

Collaborator: Pfizer

Stanford Investigator(s):


  • Drug: Maraviroc along with an optimized background antiretroviral drug regimen
  • Drug: Optimized background antiretroviral drug regimen without maraviroc


Inclusion Criteria:

   - Treatment experienced, HIV-1 infected patients

   - 18 years or older

   - Receive an approved assay for determination of HIV-1 tropism

Exclusion Criteria:

   - Pregnant or lactating

   - Using CCR5 inhibitor other than maraviroc

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Debbie Slamowitz
(650) 723-2808
Not Recruiting